Human Oncology & Pathogenesis Program
The Ping Chi Lab
Research
It is well recognized that the cellular context contributes to susceptibility to oncogenic transformation mediated by different “driver” oncogenes. The focus of our laboratory is to discover and understand the critical genetic and epigenetic factors that determine the cellular-context-dependent oncogenesis in distinct cancer types, with a primary focus on sarcoma and melanoma. We use multimodality approaches, including transcriptome analyses, epigenome mapping, and gene-expression-based high-throughput screens, as well as murine models to understand the mechanisms of pathogenesis and to develop biomarkers and targeted therapies based on insight into disease pathogenesis.
Featured News
Publications
Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Burd CE, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G. Melanoma models for the next generation of therapies. Cancer Cell. 2021 May 10;39(5):610-631.
Saqcena M, Leandro-Garcia LJ, Maag JLV, Tchekmedyian V, Krishnamoorthy GP, Tamarapu PP, Tiedje V, Reuter V, Knauf JA, de Stanchina E, Xu B, Liao XH, Refetoff S, Ghossein R, Chi P, Ho AL, Koche RP, Fagin JA. SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies. Cancer Discov. 2021 May;11(5):1158-1175.
Rousseau B, Foote MB, Maron SB, Diplas BH, Lu S, Argilés G, Cercek A, Diaz LA Jr. The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. N Engl J Med. 2021 Mar 25;384(12):1168-1170.
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021 Mar 9;5(5):1552-1564.
Hitchman TD, Bayshtok G, Ceraudo E, Moore AR, Lee C, Jia R, Wang N, Pachai MR, Shoushtari AN, Francis JH, Guan Y, Chen J, Chang MT, Taylor BS, Sakmar TP, Huber T, Chi P, Chen Y. Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. Clin Cancer Res. 2021 Mar 1;27(5):1476-1490.
People
Ping Chi, MD, PhD
- Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.
- MD, Weill Cornell Medical College
- PhD, The Rockefeller University
- View physician profile
- Physician profile
Members
- BS, University of Puerto Rico, Rio Piedras
Lab Alumni
Lab Affiliations
Achievements
- Kimmel Scholar Award, Sidney Kimmel Foundation (2012)
- Research Grant, Sarcoma Foundation of America (2012)
- Grant, GIST Cancer Awareness Foundation (2012)
- Director’s New Innovator Award, National Institutes of Health (2012)
- Clinical Scientist Development Award, National Instistutes of Health (2011)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
Career Opportunities
Get in Touch
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ping Chi discloses the following relationships and financial interests:
-
Zai Lab
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.